Medindia

X

Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns

Thursday, April 14, 2016 Respiratory Disease News J E 4
Advertisement

LONDON, April 14, 2016 /PRNewswire/ -- SummaryAsthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may be the result of a combination of factors, although two major factors thought to be involved are environmental exposure and host factors, particularly genes.Asthma treatment can be classed as either a long-term control medication, aimed at controlling persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs – but not as monotherapies – for moderate or severe persistent asthma. Currently, only one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment of allergic asthma in the Asia-Pacific region.  Nevertheless, significant unmet need remains for the treatment of severe eosinophilic asthma.ScopeThe current asthma market in the Asia-Pacific region contains novel products, including Xolair, a recombinant humanized monoclonal anti-IgE antibody; Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo, an ICS-LABA combination therapy, and Spiriva, a LAMA.- What are the competitive advantages of the existing novel drugs?With over 274 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, with improved dosing regimens and administration routes in comparison to currently marketed products.- Which classes of novel drugs are most prominent within the pipeline?- Is there strong potential for the pipeline to address unmet needs within the asthma market – specifically for severe eosinophilic asthma?Analysis of clinical trials since 2006 has identified that the failure rates of asthma molecules were highest in Phase III (46%), with the overall attrition rate for asthma in development being 78%. - How do failure rates vary by product stage of development, molecule type, and mechanism of action?- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?Over the 2014–2021 forecast period, the asthma therapeutics market in the Asia-Pacific region is expected to increase in value at a Compound Annual Growth Rate (CAGR) of 7.2%, from $3.5 billion to over $5.6 billion.- Which markets make the most significant contribution to the current market size?- What are the epidemiology trends in these markets?- Will new market entrants lead to substantial changes in annual therapy costs?- How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?Rising asthma prevalence and uptake of newer biologics will lead to significant market growth over the forecast period, in spite of affordability concerns.- Will affordability threaten the commercial success of existing drugs as well as newer biologics?- Which of the assessed countries have affordability concerns?Reasons to buyThis report will enable you to - - Understand the clinical context of asthma by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.- Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in asthma by examining clinical trial data and multi-scenario product forecast projections.- Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, South Korea and Japan.- Discover trends in licensing and co-development deals concerning asthma products and identify the major strategic consolidations that have shaped the commercial landscape.Download the full report: https://www.reportbuyer.com/product/3752600/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com  Tel: +44 208 816 85 48 Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/asthma-therapeutics-in-asia-pacific-markets-to-2021---high-prevalence-and-launch-of-late-stage-biologics-will-drive-the-market-in-spite-of-affordability-concerns-300251151.html

SOURCE ReportBuyer

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Alzheimer's Therapeutics in Asia-Pacific Markets t...
S
Atopic dermatitis: An increased focus on developme...